{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:25:22Z","timestamp":1790796322474,"version":"4.1.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. We sought to investigate the impact of these medications in a real-world cardiology practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of 17 patients with either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) levels above the treatment target despite maximally tolerated statins. Baseline lipid profile was compared with a repeat lipid profile obtained 4 to 6 weeks after initiating treatment with a PCSK9 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The average duration of PCSK9 inhibitor treatment was 10.7 months. Lipid profile comparison showed that total cholesterol decreased from 243\u2009\u00b1\u200972 to 148\u2009\u00b1\u200939 (mg\/dL) (39% reduction), triglycerides decreased from 185\u2009\u00b1\u200986 to 149\u2009\u00b1\u200962 (mg\/dL) (19.5% reduction), high-density lipoprotein cholesterol increased from 56\u2009\u00b1\u200920 to 62\u2009\u00b1\u200926 (mg\/dL) (10.7% increase), and LDL-C decreased from 154\u2009\u00b1\u200930 to 57\u2009\u00b1\u200932 (mg\/dL) (63% reduction) from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PCSK9 inhibitors as add-on therapy to maximally tolerated statins resulted in an approximately 63% reduction in LDL-C.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060518800595","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T07:34:57Z","timestamp":1538552097000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world use of PCSK9 inhibitors: A single-center experience"],"prefix":"10.1177","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-2708","authenticated-orcid":false,"given":"Sinan","family":"Sarsam","sequence":"first","affiliation":[{"name":"Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Berry","sequence":"additional","affiliation":[{"name":"Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Degheim","sequence":"additional","affiliation":[{"name":"Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby","family":"Singh","sequence":"additional","affiliation":[{"name":"Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Zughaib","sequence":"additional","affiliation":[{"name":"Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"key":"bibr1-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17018-9"},{"key":"bibr2-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"issue":"12","key":"bibr3-0300060518800595","first-page":"1270","volume":"23","author":"Menzin J","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr4-0300060518800595","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2016.060"},{"key":"bibr5-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"bibr6-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"bibr7-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"bibr8-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200061022"},{"key":"bibr9-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1427"},{"key":"bibr10-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2340"},{"key":"bibr11-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr035"},{"key":"bibr12-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"bibr13-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"issue":"1","key":"bibr14-0300060518800595","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Writing Committee","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"bibr15-0300060518800595","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.25790"},{"key":"bibr16-0300060518800595","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666170201161631"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060518800595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060518800595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060518800595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:49:49Z","timestamp":1777459789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060518800595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/0300060518800595"],"URL":"https:\/\/doi.org\/10.1177\/0300060518800595","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]}}}